The Motley Fool
29 Sept 2026, 09:21 UTC · 1h ago
Verdict
Headline takes no side. We score BMY +0.40 across four claims — moderately bullish.
+0.40moderately bullish
More positive than 67% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish · 0 new · 4 priced in
Bristol Myers Squibb faces a major patent cliff in 2028 when flagship drugs Eliquis and Opdivo lose exclusivity.
Priced inanalysis of long-term valuation range
So whatThe loss of these two core assets threatens the current $130B market cap if new product growth fails to offset the revenue gap.
More negative than 99% of claims this week
Management expects Eliquis sales to decrease by as much as $2 billion next year.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
Priced inanalysis of guidance updates
So whatThis projected drop contributes to the expected 5.6% decline in EPS from $6.95 this year to $6.56 next year.
More negative than 94% of claims this week
The company's growth portfolio grew 15% year-over-year to $7.6 billion in the last quarter.
Priced inanalysis of last quarter results
So whatGrowth from Reblozyl, Breyanzi, and Camzyos offset a 5.2% decline in the legacy portfolio to drive total revenue to $13 billion.
More positive than 87% of claims this week
Bristol Myers Squibb is currently trading at a price-to-earnings (P/E) ratio of 9 based on 2026 estimates.
Priced inanalysis of analyst estimates
So whatA re-rating to a mid-teens multiple would represent a ~50% increase in the stock price if 2027-2028 results beat fears.
More positive than 66% of claims this week
Which stocks this story touches
More positive than 67% of ticker scores this week
While facing patent cliffs, the company shows successful execution of mitigation efforts and trades at a low valuation.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
The Motley Fool
1h ago
—
BMY hasn't traded since this ran. Last close $63.88 (Sep 28); the reaction starts at the next open.
BMY chart →
